Back to results
US 12,594,305 B2Granted
Bone marrow microglia progenitor cells and uses thereof
AssigneeStrominnate Therapeutics AB
InventorTania Ramos Moreno
Life of this patent
Estimating the term…
Abstract
The present disclosure concerns a microglia progenitor cell derived from bone marrow and/or placental stromal cells and/or umbilical cord stromal cell and methods for their isolation; as well as use of said cells for therapy of disorders of the CNS.
Claims6
A method for manufacturing an enriched population of microglia cells, the method comprising the steps of:
- a) providing a sample A and a sample B, both comprising bone marrow stromal cells and/or placenta stromal cells and/or umbilical cord stromal cells;
- b) isolating CD11b+, CD45− microglia progenitor cells from sample A;
- c) i) contacting sample B with a culturing media comprising serum, thereby expanding the bone marrow stromal cells and/or placenta stroma cells and/or umbilical cord stromal cells into mesenchymal stem cells (MSCs);
- or
- ii) providing MSCs in a culturing media comprising serum;
- d) contacting the CD11b+, CD45− microglia progenitor cells of sample A, step (b), with the MSCs of step (c) to generate a sample C;
- e) removing the media comprising serum from sample C;
- f) contacting the serum free sample C of step (e) with a substantially serum free media wherein serum in the substantially serum free media is below detection limits, the substantially serum free media comprising at least one growth factor selected from the group consisting of brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), neurotrophin-3 (NT-3);
- neurotrophic 4 (NT-4) and glial cell line-derived neurotrophic factor (GDNF);
- thereby expanding and differentiating the CD11b+, CD45− microglia progenitor cells;
- g) obtaining an enriched population of microglia cells.
8 more elements
Dependencies are inferred from the claim text.